Ariad Pharmaceuticals (ARIA) stock was feeling some Mylan Pharmaceutical (MYL)-like pressure Monday on Congress’ looming deadline to submit information regarding an $80,000 price increase for a rare cancer drug.
Over the past year, Ariad upped its price on Inclusig to $199,000 annually from $120,000, RBC analyst Michael Yee wrote in a research report. Inclusig treats specific classes of chronic myeloid leukemia and acute lymphoblastic leukemia.
